Annual EBITDA
-$21.17 M
+$3.36 M+13.71%
December 31, 2023
Summary
- As of February 8, 2025, BCLI annual EBITDA is -$21.17 million, with the most recent change of +$3.36 million (+13.71%) on December 31, 2023.
- During the last 3 years, BCLI annual EBITDA has risen by +$10.29 million (+32.71%).
- BCLI annual EBITDA is now -116240.66% below its all-time high of -$18.20 thousand, reached on March 31, 2002.
Performance
BCLI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$2.99 M
-$71.00 K-2.43%
September 30, 2024
Summary
- As of February 8, 2025, BCLI quarterly EBITDA is -$2.99 million, with the most recent change of -$71.00 thousand (-2.43%) on September 30, 2024.
- Over the past year, BCLI quarterly EBITDA has dropped by -$71.00 thousand (-2.43%).
- BCLI quarterly EBITDA is now -1223.68% below its all-time high of $266.00 thousand, reached on December 31, 2017.
Performance
BCLI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$13.05 M
+$2.98 M+18.59%
September 30, 2024
Summary
- As of February 8, 2025, BCLI TTM EBITDA is -$13.05 million, with the most recent change of +$2.98 million (+18.59%) on September 30, 2024.
- Over the past year, BCLI TTM EBITDA has increased by +$2.98 million (+18.59%).
- BCLI TTM EBITDA is now -241659.26% below its all-time high of -$5400.00, reached on June 30, 2002.
Performance
BCLI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
BCLI EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.7% | -2.4% | +18.6% |
| 3 y3 years | +32.7% | -2.4% | +18.6% |
| 5 y5 years | -51.8% | -2.4% | +18.6% |
BCLI EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +13.7% | -24.0% | +60.3% | at high | +49.5% |
| 5 y | 5-year | at high | +32.7% | -24.0% | +73.8% | at high | +58.5% |
| alltime | all time | <-9999.0% | +32.7% | -1223.7% | +82.0% | <-9999.0% | +58.5% |
Brainstorm Cell Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.99 M(+2.4%) | -$13.05 M(-18.6%) |
| Jun 2024 | - | -$2.92 M(+21.1%) | -$16.04 M(-13.3%) |
| Mar 2024 | - | -$2.41 M(-49.1%) | -$18.50 M(-12.6%) |
| Dec 2023 | -$21.17 M(-13.7%) | -$4.74 M(-20.6%) | -$21.17 M(-0.5%) |
| Sep 2023 | - | -$5.97 M(+10.9%) | -$21.28 M(-3.6%) |
| Jun 2023 | - | -$5.38 M(+5.9%) | -$22.08 M(-8.8%) |
| Mar 2023 | - | -$5.08 M(+4.9%) | -$24.22 M(-1.3%) |
| Dec 2022 | -$24.54 M(+1.1%) | -$4.84 M(-28.4%) | -$24.54 M(-5.0%) |
| Sep 2022 | - | -$6.77 M(-10.0%) | -$25.83 M(+6.4%) |
| Jun 2022 | - | -$7.52 M(+39.2%) | -$24.27 M(+6.4%) |
| Mar 2022 | - | -$5.40 M(-12.1%) | -$22.81 M(-6.0%) |
| Dec 2021 | -$24.28 M(-22.8%) | -$6.14 M(+17.9%) | -$24.28 M(-17.9%) |
| Sep 2021 | - | -$5.21 M(-14.0%) | -$29.56 M(+2.7%) |
| Jun 2021 | - | -$6.06 M(-11.8%) | -$28.78 M(-4.3%) |
| Mar 2021 | - | -$6.87 M(-39.9%) | -$30.07 M(-4.4%) |
| Dec 2020 | -$31.46 M(+37.8%) | -$11.43 M(+158.0%) | -$31.46 M(+13.8%) |
| Sep 2020 | - | -$4.43 M(-39.7%) | -$27.65 M(-3.8%) |
| Jun 2020 | - | -$7.35 M(-11.0%) | -$28.74 M(+9.6%) |
| Mar 2020 | - | -$8.26 M(+8.5%) | -$26.21 M(+14.8%) |
| Dec 2019 | -$22.84 M(+63.7%) | -$7.62 M(+38.1%) | -$22.84 M(+10.7%) |
| Sep 2019 | - | -$5.51 M(+14.3%) | -$20.64 M(+12.6%) |
| Jun 2019 | - | -$4.82 M(-1.2%) | -$18.32 M(+10.7%) |
| Mar 2019 | - | -$4.88 M(-9.8%) | -$16.55 M(+18.6%) |
| Dec 2018 | -$13.95 M(+183.9%) | -$5.42 M(+69.3%) | -$13.95 M(+68.7%) |
| Sep 2018 | - | -$3.20 M(+4.7%) | -$8.27 M(+11.2%) |
| Jun 2018 | - | -$3.06 M(+33.9%) | -$7.44 M(+36.7%) |
| Mar 2018 | - | -$2.28 M(-957.9%) | -$5.44 M(+10.7%) |
| Dec 2017 | -$4.91 M(-1.8%) | $266.00 K(-111.2%) | -$4.91 M(-15.4%) |
| Sep 2017 | - | -$2.37 M(+124.1%) | -$5.81 M(+14.8%) |
| Jun 2017 | - | -$1.06 M(-39.7%) | -$5.06 M(+1.9%) |
| Mar 2017 | - | -$1.75 M(+179.3%) | -$4.96 M(-0.8%) |
| Dec 2016 | -$5.01 M(-40.8%) | -$628.00 K(-61.3%) | -$5.01 M(-13.1%) |
| Sep 2016 | - | -$1.62 M(+68.7%) | -$5.76 M(-13.8%) |
| Jun 2016 | - | -$961.00 K(-46.5%) | -$6.68 M(-17.1%) |
| Mar 2016 | - | -$1.80 M(+29.9%) | -$8.06 M(-4.8%) |
| Dec 2015 | -$8.45 M(+13.9%) | -$1.38 M(-45.7%) | -$8.47 M(-13.2%) |
| Sep 2015 | - | -$2.54 M(+8.8%) | -$9.76 M(+1.2%) |
| Jun 2015 | - | -$2.34 M(+6.1%) | -$9.64 M(+12.2%) |
| Mar 2015 | - | -$2.21 M(-17.3%) | -$8.60 M(+15.8%) |
| Dec 2014 | -$7.42 M(+47.2%) | -$2.67 M(+9.7%) | -$7.42 M(+20.5%) |
| Sep 2014 | - | -$2.43 M(+87.8%) | -$6.16 M(+28.2%) |
| Jun 2014 | - | -$1.29 M(+25.5%) | -$4.80 M(-3.8%) |
| Mar 2014 | - | -$1.03 M(-26.4%) | -$4.99 M(-1.0%) |
| Dec 2013 | -$5.04 M | -$1.40 M(+30.2%) | -$5.04 M(+17.9%) |
| Sep 2013 | - | -$1.08 M(-27.5%) | -$4.28 M(-2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$1.49 M(+37.4%) | -$4.37 M(+17.5%) |
| Mar 2013 | - | -$1.08 M(+70.2%) | -$3.72 M(+5.7%) |
| Dec 2012 | -$3.52 M(-9.7%) | -$635.00 K(-45.8%) | -$3.52 M(-17.9%) |
| Sep 2012 | - | -$1.17 M(+40.7%) | -$4.29 M(+12.4%) |
| Jun 2012 | - | -$833.00 K(-5.2%) | -$3.81 M(-12.5%) |
| Mar 2012 | - | -$879.00 K(-37.3%) | -$4.36 M(+9.8%) |
| Dec 2011 | -$3.89 M(+74.0%) | -$1.40 M(+100.4%) | -$3.97 M(+29.3%) |
| Sep 2011 | - | -$700.00 K(-49.2%) | -$3.07 M(+3.6%) |
| Jun 2011 | - | -$1.38 M(+181.0%) | -$2.96 M(+34.5%) |
| Mar 2011 | - | -$490.00 K(-2.8%) | -$2.20 M(-5.1%) |
| Dec 2010 | -$2.24 M(+41.5%) | -$504.00 K(-15.0%) | -$2.32 M(+21.5%) |
| Sep 2010 | - | -$593.00 K(-3.7%) | -$1.91 M(0.0%) |
| Jun 2010 | - | -$616.00 K(+1.1%) | -$1.91 M(+5.1%) |
| Mar 2010 | - | -$609.00 K(+554.8%) | -$1.82 M(+3.9%) |
| Dec 2009 | -$1.58 M(-49.2%) | -$93.00 K(-84.3%) | -$1.75 M(-25.0%) |
| Sep 2009 | - | -$593.00 K(+13.2%) | -$2.33 M(-4.3%) |
| Jun 2009 | - | -$524.00 K(-3.0%) | -$2.44 M(-1.7%) |
| Mar 2009 | - | -$540.00 K(-20.0%) | -$2.48 M(-11.6%) |
| Dec 2008 | -$3.12 M(-34.4%) | -$675.00 K(-3.2%) | -$2.80 M(+3.0%) |
| Sep 2008 | - | -$697.00 K(+23.1%) | -$2.72 M(-4.2%) |
| Jun 2008 | - | -$566.00 K(-34.6%) | -$2.84 M(+7.3%) |
| Mar 2008 | - | -$866.00 K(+46.0%) | -$2.65 M(+6.5%) |
| Dec 2007 | -$4.75 M(+520.6%) | -$593.00 K(-27.3%) | -$2.49 M(+31.3%) |
| Sep 2007 | - | -$816.00 K(+119.4%) | -$1.89 M(+26.2%) |
| Jun 2007 | - | -$371.90 K(-47.2%) | -$1.50 M(-3.4%) |
| Mar 2007 | - | -$704.30 K(+66.7%) | -$1.55 M(+37.5%) |
| Dec 2006 | -$766.00 K(-62.1%) | - | - |
| Sep 2006 | - | -$422.60 K(-0.3%) | -$1.13 M(-35.0%) |
| Jun 2006 | - | -$423.90 K(+96.5%) | -$1.73 M(-4.8%) |
| Mar 2006 | - | -$215.70 K(+229.8%) | -$1.82 M(-1.6%) |
| Mar 2006 | -$2.02 M(-88.9%) | - | - |
| Dec 2005 | - | -$65.40 K(-93.6%) | -$1.85 M(-89.9%) |
| Sep 2005 | - | -$1.03 M(+101.2%) | -$18.39 M(-2.9%) |
| Jun 2005 | - | -$511.50 K(+108.0%) | -$18.93 M(+2.8%) |
| Mar 2005 | -$18.24 M(>+9900.0%) | -$245.90 K(-98.5%) | -$18.42 M(+1.2%) |
| Dec 2004 | - | -$16.60 M(+954.4%) | -$18.21 M(+1025.0%) |
| Sep 2004 | - | -$1.57 M(+4323.0%) | -$1.62 M(+2806.5%) |
| Mar 2004 | -$73.10 K(+190.1%) | -$35.60 K(+309.2%) | -$55.70 K(+145.4%) |
| Dec 2003 | - | -$8700.00(+70.6%) | -$22.70 K(+20.7%) |
| Sep 2003 | - | -$5100.00(-19.0%) | -$18.80 K(+9.3%) |
| Jun 2003 | - | -$6300.00(+142.3%) | -$17.20 K(+5.5%) |
| Mar 2003 | -$25.20 K(+38.5%) | -$2600.00(-45.8%) | -$16.30 K(+19.0%) |
| Dec 2002 | - | -$4800.00(+37.1%) | -$13.70 K(+53.9%) |
| Sep 2002 | - | -$3500.00(-35.2%) | -$8900.00(+64.8%) |
| Jun 2002 | - | -$5400.00 | -$5400.00 |
| Mar 2002 | -$18.20 K | - | - |
FAQ
- What is Brainstorm Cell Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual EBITDA year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly EBITDA year-on-year change?
- What is Brainstorm Cell Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics TTM EBITDA year-on-year change?
What is Brainstorm Cell Therapeutics annual EBITDA?
The current annual EBITDA of BCLI is -$21.17 M
What is the all time high annual EBITDA for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual EBITDA is -$18.20 K
What is Brainstorm Cell Therapeutics annual EBITDA year-on-year change?
Over the past year, BCLI annual EBITDA has changed by +$3.36 M (+13.71%)
What is Brainstorm Cell Therapeutics quarterly EBITDA?
The current quarterly EBITDA of BCLI is -$2.99 M
What is the all time high quarterly EBITDA for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly EBITDA is $266.00 K
What is Brainstorm Cell Therapeutics quarterly EBITDA year-on-year change?
Over the past year, BCLI quarterly EBITDA has changed by -$71.00 K (-2.43%)
What is Brainstorm Cell Therapeutics TTM EBITDA?
The current TTM EBITDA of BCLI is -$13.05 M
What is the all time high TTM EBITDA for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high TTM EBITDA is -$5400.00
What is Brainstorm Cell Therapeutics TTM EBITDA year-on-year change?
Over the past year, BCLI TTM EBITDA has changed by +$2.98 M (+18.59%)